論文

査読有り
2015年4月

Percutaneous Radiofrequency Ablation of Lung Cancer Presenting as Ground-Glass Opacity

CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY
  • Toshihiro Iguchi
  • ,
  • Takao Hiraki
  • ,
  • Hideo Gobara
  • ,
  • Hiroyasu Fujiwara
  • ,
  • Yusuke Matsui
  • ,
  • Junichi Soh
  • ,
  • Shinichi Toyooka
  • ,
  • Katsuyuki Kiura
  • ,
  • Susumu Kanazawa

38
2
開始ページ
409
終了ページ
415
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1007/s00270-014-0926-x
出版者・発行元
SPRINGER

We retrospectively evaluated the outcomes of lung cancer patients presenting with ground-glass opacity (GGO) who received radiofrequency ablation (RFA).
Sixteen patients (5 men and 11 women; mean age, 72.6 years) with 17 lung cancer lesions showing GGO (mean long axis diameter, 1.6 cm) underwent a total of 20 percutaneous computed tomography (CT) fluoroscopy-guided RFA sessions, including three repeated sessions for local progression. Lung cancer with GGO was defined as a histologically confirmed malignant pulmonary lesion with a GGO component accounting for > 50 % of the lesion on high-resolution CT. Procedure outcomes were evaluated.
There were no major complications. Pneumothorax occurred in 15 of 20 treatment sessions: 14 were asymptomatic, and 1 required chest tube placement but resolved satisfactorily within 48 h. Minor pulmonary hemorrhage occurred in two and mild pneumonitis in one. The median tumor follow-up period was 61.5 (range 6.1-96.6) months. The effectiveness rates of the primary and secondary techniques were 100 and 100 % at 1 year, 93.3 and 100 % at 2 years, and 78.3 and 92.3 % at 3 years, respectively. The median patient follow-up period was 65.6 (range 6.1-96.6) months. One patient died owing to recurrent other cancer 11.7 months after RFA, whereas the other 15 remained alive. Overall survival and disease-specific survival rates were 93.3 and 100 % at 1 year and 93.3 and 100 % at 5 years, respectively.
RFA for lung cancer with GGO was safe and effective, and resulted in promising survival rates.

リンク情報
DOI
https://doi.org/10.1007/s00270-014-0926-x
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/24938905
Web of Science
https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000351155100020&DestApp=WOS_CPL
ID情報
  • DOI : 10.1007/s00270-014-0926-x
  • ISSN : 0174-1551
  • eISSN : 1432-086X
  • PubMed ID : 24938905
  • Web of Science ID : WOS:000351155100020

エクスポート
BibTeX RIS